Scholars Central

Conference abstractPublished 7 Dec 2018

Synergistic combinations of chromatin modifiers as a potential treatment approach for gliomas

Authors: Arshak R Alexanian

Cell Reprogramming and Therapeutics, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A series of seminal discoveries made over the last decade have shown that critical changes in cancer cells, such as silencing of tumor suppressor genes and activation of oncogenes, are caused not only by genetics but also by epigenetic mechanisms. Although epigenetic changes are somatically heritable, in contrast to genetic changes, they are potentially reversible, making them good targets for therapeutic intervention. Covalent modifications of chromatin, such as methylation and acetylation of histones and methylation of DNA,are important components of epigenetic machinery. Several recent studies have shown that epigenetic modifiers are candidates for potent new drugs in multiple cancers therapies, including gliomas, and several clinical trials are ongoing. However, as with other chemotherapeutic drugs, toxicity is one of the main concerns with some of the potent epigenetic drugs. Synergistic combinations of these agents are one approach to overcoming toxicity issues and enhancing efficacy. In our previous studies, we demonstrated that specific combinations of histone methyltransferase (HMT) and deacetylase (HDAC) inhibitors significantly attenuated the viability of D54 cells, but had only a small effect on normal stem cell growth. Recently, we demonstrated that these combinations exhibit a similar effect also on other glioma cell lines. All these studies suggest that specific combinations of histone covalent modifiers could be an effective treatment option for several types of gliomas.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Oncology Translational Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Arshak R Alexanian”